N-terminal pro-brain natriuretic peptide levels had an independent and added ability in the evaluation of all-cause mortality in older Chinese patients with atrial fibrillation-Reference-Cited by-全球学者库

N-terminal pro-brain natriuretic peptide levels had an independent and added ability in the evaluation of all-cause mortality in older Chinese patients with atrial fibrillation

Published:2019-02-28 Issue:1 Volume:19 Page:
ISSN:1471-2318
Container-title:BMC Geriatrics
language:en
Short-container-title:BMC Geriatr

Author:

Fu Shihui,Jiao Jie,Guo Yi,Zhu Bing,Luo Leiming

Funder

National Geriatric Disease Clinical Medicine Research Center Project

Publisher

Springer Science and Business Media LLC

Subject

Geriatrics and Gerontology

Link

http://link.springer.com/content/pdf/10.1186/s12877-019-1051-0.pdf

Reference16 articles.

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285:2370–5.

2. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369–429.

3. Shahid F, Lip GYH. Risk stratification models in atrial fibrillation. Semin Thromb Hemost. 2017;43:505–13.

4. Tu HT, Campbell BC, Meretoja A, Churilov L, Lees KR, Donnan GA, Davis SM. Pre-stroke CHADS2 and CHA2DS2-VASc scores are useful in stratifying three-month outcomes in patients with and without atrial fibrillation. Cerebrovasc Dis. 2013;36:273–80.

5. Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, Gersh BJ, Hanna M, Hohnloser S, Horowitz J, Huber K, Hylek EM, Lopes RD, McMurray JJ, Granger CB. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE trial (Apixaban for the prevention of stroke in subjects with atrial fibrillation). J Am Coll Cardiol. 2013;61:2274–84.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnostic and Prognostic Value of Aminoterminal Prohormone of Brain Natriuretic Peptide in Heart Failure with Mildly Reduced Ejection Fraction Stratified by the Degree of Renal Dysfunction;Journal of Clinical Medicine;2024-01-16

2. Anemia and iron deficiency in patients with atrial fibrillation;BMC Cardiovascular Disorders;2022-05-04

3. Influence of hemoglobin concentration on the in-hospital outcomes in newly diagnosed heart failure patients with atrial fibrillation;Medicine;2022-03-04

4. Heart failure with preserved ejection fraction based on aging and comorbidities;Journal of Translational Medicine;2021-07-06

5. Association of natriuretic peptide and adverse outcomes in patients with atrial fibrillation: A meta‐analysis;Clinical and Experimental Pharmacology and Physiology;2020-11-30